GSP Crop Science IPO Day 1: Check Latest GMP, Subscription Status, Key Highlights, and More
The GSP Crop Science IPO is open for public subscription today, 16 March 2026. Prior to the IPO opening, the company had raised ₹120 crore from anchor investors on March 13, 2026.
GSP Crop Science IPO: Issue Details
Issue Type: The IPO is a book-build issue of ₹400 crore, consisting of a fresh issue of ₹250 crore and an offer for sale (OFS) of ₹160 crore.
Lot Size: 46 shares
Price Band: ₹304-₹320 per share
Minimum Investment: ₹14,720 per lot for retail investors (at the cut-off price or upper price band)
IPO Closing Date: March 18, 2026
Allotment Date: The basis of allotment will be finalised by March 20, 2026.
Listing Date: The tentative listing date on BSE and NSE is March 24, 2026.
Book Running Lead Manager: Equirus Capital Private Limited and Motilal Oswal Investment Advisors Limited
Registrar: MUFG Intime India Private Limited
GSP Crop Science IPO Day 1 Subscription Status
[16-March-2026 10:51:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.00 |
|
Non-Institutional Investors |
0.00 |
|
Retail Individual Investors (RIIs) |
0.02 |
|
Total |
0.01 |
Utilisation of IPO Proceeds
The net proceeds from the fresh issue will be used to fund the expenses towards the following objectives:
- Repay/prepay outstanding borrowings
- General corporate purposes
Explore other Upcoming IPOs on BSE and NSE.
GSP Crop Science IPO GMP
As per media reports, the Grey Market Premium (GMP) of GSP Crop Science is reported at ₹0 over the IPO price.
GSP Crop Science Business Overview
GSP Crop Science is a research-driven agrochemical company with over 40 years of experience in the industry. The company specialises in the development and manufacturing of insecticides, herbicides, fungicides and plant growth regulators in India.
As of September 30, 2025, the company has secured 524 product registrations across formulations and technical portfolios, granted 102 patents to date and has 108 additional patent applications under review.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.